Rolontis and Leclaza make their place in Korea
By Chon, Seung-Hyun | translator Alice Kang
22.11.29 06:20:57
가나다라
0
Yuhan’s Leclaza exceeds annual sales of KRW 10 billion for 2 consecutive years since its launch...global trials are also smoothly underway
Hanmi’s Rolontis raises initial sales of KRW 1.5 billion in Korea... starts sales in the US
Leclaza and Rolontis, the homegrown drugs that have gained attention as promising new global drugs, have made a smooth start in the domestic market. Yuhan Corp’s Leclaza’s annual sales exceeded KRW 10 billion in the second year of release, and Hanmi Pharmaceutical’s Rolontis has also started making sales in earnest in the Korean market.
◆Yuhan’s Leclaza’s sales exceed KRW 10 billion in only 3 quarters... nears FDA approval
According to the market research institution IQVIA on the 28th, Leclaza’s sales in Q3 were KRW 4.6 billion, a threefold increase from the KRW 1.5 billion in the same period of the previous year.
Chon, Seung-Hyun(1000@dailypharm.com)
If you want to see the full article, please JOIN US (click)